Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® — EMIX

Essential Thrombocythemia (ET) Clinical Trial

Official title:
An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)

Status Completed

Clinical Trial Summary

This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01352585
Study type	Observational
Source	Takeda
Contact
Status	Completed
Phase
Start date	July 19, 2011
Completion date	September 19, 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01198717` - Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Completed	`NCT01214915` - Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia	Phase 3
Completed	`NCT01467661` - Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia	Phase 3
Active, not recruiting	`NCT02577926` - The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Phase 2
Completed	`NCT03625895` - Agrylin Drug Use-Result Survey
Completed	`NCT01816256` - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms	N/A
Completed	`NCT04243122` - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients	Phase 2